Rapid quantification of gabapentin, pregabalin, and vigabatrin in human serum by ultraperformance liquid chromatography with mass-spectrometric detection

Therapeutic Drug Monitoring

Volumn 35, Issue 1, 2013, Pages 48-53

  Chahbouni, Abdel ^a   Sinjewel, Arno ^a   G Den Burger, Jeroen C ^a   Vos, René M ^a   Wilhelm, Abraham J ^a   Veldkamp, Agnes I ^a   Swart, Eleanora L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

anticonvulsant; gabapentin; LC MS; pregabalin; vigabatrin

Indexed keywords

GABAPENTIN; PREGABALIN; VIGABATRIN;

ACCURACY; ARTICLE; CONCENTRATION (PARAMETERS); DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MONITORING; ENVIRONMENTAL TEMPERATURE; HUMAN; HUMAN TISSUE; ION CURRENT; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MONITORING; PRIORITY JOURNAL; STANDARD; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

AMINES; ANTICONVULSANTS; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANECARBOXYLIC ACIDS; DRUG STABILITY; GAMMA-AMINOBUTYRIC ACID; HUMANS; TANDEM MASS SPECTROMETRY; VIGABATRIN;

EID: 84872841734     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31827788c0     Document Type: Article

References (21)

1. Browne TR, Holmes GL. Handbook of Epilepsy. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008.
2. Watanabe M, Maemura K, Kanbara K, et al. GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol. 2002;213: 1-47.
3. Eroglu Ç, Allen NJ, Susman MW, et al. Gabapentin receptor a2d-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009;139:380-392.
4. Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gammaaminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007;29:26-48.
5. Hamandi K, Sander JW. Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure. 2006;15:73-78.
6. Wallace SJ. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev. 2001:23;227-283.
7. Mercolini L, Mandrioli R, Amore M, et al. Simultaneous HPLC-F analysis of three recent antiepileptic drugs in human plasma. J Pharm Biomed Anal. 2010;53:62-67.
8. Wad N, Krämer G. Sensitive high-performance liquid chromatographic method with fluorometric detection for the simultaneous determination of gabapentin and vigabatrin in serum and urine. J Chromatogr B Biomed Sci Appl. 1998;705:154-158.
9. Yagi T, Naito T, Mino Y, et al. Rapid and validated fluorometric HPLC method for determination of gabapentin in human plasma and urine for clinical application. J Clin Pharm Ther. 2012;37:89-94.
10. Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther Drug Monit. 2005;27:451-456.
11. Vermeij TA, Edelbroek PM. Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phthaldialdehyde and fluorescence detection. J Chromatogr B Anal Technol Biomed Life Sci. 2004; 810:297-303.
12. Mandal U, Sarkar AK, Gowda KV, et al. Determination of pregablin in human plasma using LC-MS-MS. Chromatographia. 2008;67:237-243.
13. Wattananat T, Akarawut W. Validated LC-MS-MS method for the determination of gabapentin in human plasma: application to a bioequivalence study. J Chromatogr Sci. 2009;47:868-871.
14. Oertel R, Arenz N, Pietsch J, et al. Simultaneous determination of three anticonvulsants using hydrophilic interaction LC-MS. J Sep Sci. 2009; 32:238-243.
15. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res. 2000;12:1551-1557.
16. Rosing H, Man WY, Doyle E, et al. Bioanalytical liquid chromatography method validation. A review of current practices and procedures. J Liq Chrom Rel Technol. 2000;23:329-354.
17. Dadgar D, Burnett PE. Issues in evaluation of bioanalytical method selectivity and drug stability. J Pharm Biomed Anal. 1995:14;23-31.
18. U.S. Department of Health and Human Services. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for Industry, Bioanalytical Method Validation; Rockville, MD; 2001. Available at: http://www.fda.gov/cder/guidance/index.htm.
19. Matuszewski BK, Constanzer ML, Chavez-Eng CM, Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030.
20. Matuszewski BK. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:293-300.
21. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276.